PD-L1 and PD-1 inhibitors are popular immunotherapy drugs recognized for their versatility across various cancer types. These treatments block the interaction between programmed cell death protein 1 (PD-1) on immune cells and PD-L1 on tumor cells, which tumors use to evade immune detection. By inhibiting this pathway, PD-(L)1 drugs re-activate the immune system, allowing it to recognize and attack cancer cells. Cisplatin enhances this effect through its ability to induce immunogenic cell death, which complements the PD-(L)1 mechanism of action, making the combination therapy even more effective. Due to this synergy, approximately 50% of PD-(L)1 treatments today are administered alongside cisplatin or carboplatin.

Our Platin-DRP™ technology precisely identifies patients most likely to benefit from cisplatin, including in combination with PD-(L)1 immunotherapy. By filtering out patients with low Platin-DRP™ scores, the response rates for combination therapies increase significantly. This not only enhances treatment effectiveness but also minimizes patient suffering by guiding those with low Platin-DRP™ scores toward more suitable treatment options, potentially saving crucial time in their cancer journey.

With the PD-(L)1 inhibitor market projected to grow from USD $45.8 billion in 2023 to USD $105 billion by 2028, pharmaceutical companies must differentiate themselves in this rapidly growing, yet highly competitive market. 

The Platin-DRP™ offers more personalized and effective treatments, helping companies differentiate themselves in an increasingly crowded space.